Today
-0.04%
5 Days
+0.22%
1 Month
+0.95%
6 Months
+49.09%
Year to Date
+61.01%
1 Year
+21.35%
• Stryker exceeded second-quarter earnings expectations across MedSurg and Neurotechnology segments. • Management raised full-year earnings guidance citing operational efficiencies and market share gains. • Analysts maintain a Buy rating with an average price target of $385.60.
• Quarterly procedure volume growth exceeded expectations, driving the company’s recent valuation increase. • Adoption of robotic platforms and AI integration supports recurring revenue and surgical precision. • Intuitive Surgical reports $10.06 billion in annual revenue with high institutional investor support.


| Shareholders | Proportion |
|---|---|
| BlackRock Institutional Trust Company, N.A. | 14.34% |
| Vanguard Portfolio Management, LLC | 6.03% |
| Vanguard Capital Management, LLC | 4.53% |
| Dimensional Fund Advisors, L.P. | 4.37% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 51.12% |
| Investment Advisor/Hedge Fund | 38.86% |
| Hedge Fund | 13.55% |
| Research Firm | 5.95% |
Related Instruments